Most patients see more noticeable weight reduction by the 8- to 12-week mark
Right now, the focus is largely on their role in managing diabetes and obesity, but the research is really starting to show some interesting possibilities for mood disorders
: , , As hopeful as this is, a few big questions remain, especially if we care about equity and not just headlines: - Will oral GLP-1s actually be covered by insurers and employers as long term therapy, instead of short weight loss sprints followed by predictable regain - How will pricing and step edits work when a patient has already been on an injectable for more than a year - Will these trials and future studies meaningfully include the diverse, underrepresented communities that carry a disproportionate burden of obesity, sleep apnea, and cardiometabolic disease : - Set expectations early: discuss obesity as chronic disease, and proactively plan for maintenance before stopping anything
Personalized care, made easy Step 1 Get approved Share your health history, lifestyle, and goals so we can better understand you and create care that truly fits your needs
Why an 8% Pill Matters: For a patient who has severe needle phobia, lacks reliable refrigeration for injectables, or travels frequently, a drug that achieves 20% weight loss in trials but goes unused is far less effective than an 8% pill taken consistently every day
